BC Innovations | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BC Innovations | Feb 6, 2019
Distillery Therapeutics


INDICATION: Amyotrophic lateral sclerosis (ALS) Fruit fly studies suggest promoting BMPRI or BMP7 expression could help treat ALS. In a Drosophila model of ALS expressing mutant SOD1, overexpression of the Drosophila ortholog of human BMPRI...
BioCentury | Jan 5, 2018

Scholar goes to the clinic

While Scholar Rock LLC’s series C round will bring the biotech’s lead program into the clinic, investors also want continued investment in the company’s growth factor modulation platform to maximize its value. On Jan. 3,...
BC Week In Review | Aug 24, 2015
Company News

Ember Therapeutics, Knight Therapeutics deal

Ember granted Knight exclusive rights to commercialize Ember’s bone morphogenetic protein 7 ( BMP7 ; OP-1) pipeline in Canada, Israel, Russia and sub-Saharan Africa. The lead product has completed a Phase IIa trial to treat osteoarthritis....
BC Week In Review | Mar 23, 2015
Company News

Ember Therapeutics, Mariel deal

Obesity and diabetes company Ember and Mariel, which is developing compounds targeting bone morphogenetic protein 7 ( BMP7 ; OP-1), will merge and form Ember Therapeutics Inc. The companies did not disclose financial terms and could...
BC Week In Review | Mar 10, 2014
Company News

Olympus Corp. musculoskeletal news

Olympus said it will discontinue operations for its U.S. biotechnology division, Olympus Biotech Corp. , which includes a facility in Hopkinton, Mass. Olympus said it made the decision for financial reasons. Olympus Biotech will discontinue its...
BC Week In Review | Oct 29, 2012
Clinical News

NeoStem preclinical data

In severe combined immunodeficiency disease (SCID) mice with surgically-induced cranial defects, G-CSF mobilized VSELs isolated from the blood of healthy human donors and transplanted into the defects using collagen sponge scaffolds significantly increased tissue mineral...
BC Innovations | Oct 11, 2012
Cover Story

Ember: warming up to brown fat

A team led by Boston-area researchers has shown that inhibiting a cation channel dubbed TRPV4 induced white fat cells to behave like brown fat, thereby protecting mice from diet-induced obesity and insulin resistance. 1 Ember...
BC Innovations | Jul 26, 2012
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Sheep model for load-bearing long bone defects Aged sheep with defects in their long bones could be useful for evaluating bone repair and regeneration treatments....
BC Innovations | May 31, 2012
Targets & Mechanisms

Going to BAT

Two teams are reporting new targets for inducing the conversion of white fat to a brown-like phenotype, or boosting the activity of existing brown fat, that could help treat obesity and related metabolic diseases. A...
Items per page:
1 - 10 of 109